The North America Gastric Cancer Market should witness market growth of 17.1% CAGR during the forecast period (2023-2029).
Interstitial cells of Cajal, are extremely early kinds of cells in the stomach wall, are where these rare malignancies begin. Some GISTs are far more likely than others to spread to different sections of the body or to grow into new locations. GISTs can begin anywhere throughout the digestive tract, although most begin in the stomach. Cells in the stomach (or other regions of the digestive system) that operate in some ways, like nerve cells, and in other ways, like hormone-producing (endocrine) cells, are where neuroendocrine tumors (NETs) originate. The majority of NETs grow gradually and never spread to other organs; however, some do.
Scientists have identified several risk factors that increase a person's likelihood of developing gastric cancer. For example, men and women are more likely to develop gastric cancer. Although gastric cancer can develop in younger people, the risk increases with age.
In the US, 85.6 percent of adults aged 18 and older reported having consumed alcohol at some point in their lives, 69.5 percent said they had done so in the year prior, and 54.9 percent said they had done so in the previous month (59.1 percent of men and 51.0 percent of women in this age group reported having done so). In 2019, 6.3% of adults (18 and older) reported significant alcohol consumption in the same period, 25.8% of adults (18 and older) reported binge drinking in the previous month (29.7% of men in this age group and 22.2 percent of women in this age group). The market for gastric cancer is anticipated to grow in the region as a result.
The US market dominated the North America Gastric Cancer Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,377.4 million by 2029. The Canada market is poised to grow at a CAGR of 19.8% during (2023-2029). Additionally, The Mexico market should witness a CAGR of 18.7% during (2023-2029).
Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, and Radiation Therapy & Surgery. Based on Disease Type, the market is segmented into Adenocarcinoma, Carcinoid Tumor, Gastrointestinal Stromal Tumor, Lymphoma and Others. Based on Distribution Channel, the market is segmented into Specialty & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Drug Class, the market is segmented into PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Pfizer, Inc., Viatris, Inc. (Mylan N.V.), F. Hoffmann-La Roche Ltd., Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceuticals Industries Ltd., Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., and Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.).
Interstitial cells of Cajal, are extremely early kinds of cells in the stomach wall, are where these rare malignancies begin. Some GISTs are far more likely than others to spread to different sections of the body or to grow into new locations. GISTs can begin anywhere throughout the digestive tract, although most begin in the stomach. Cells in the stomach (or other regions of the digestive system) that operate in some ways, like nerve cells, and in other ways, like hormone-producing (endocrine) cells, are where neuroendocrine tumors (NETs) originate. The majority of NETs grow gradually and never spread to other organs; however, some do.
Scientists have identified several risk factors that increase a person's likelihood of developing gastric cancer. For example, men and women are more likely to develop gastric cancer. Although gastric cancer can develop in younger people, the risk increases with age.
In the US, 85.6 percent of adults aged 18 and older reported having consumed alcohol at some point in their lives, 69.5 percent said they had done so in the year prior, and 54.9 percent said they had done so in the previous month (59.1 percent of men and 51.0 percent of women in this age group reported having done so). In 2019, 6.3% of adults (18 and older) reported significant alcohol consumption in the same period, 25.8% of adults (18 and older) reported binge drinking in the previous month (29.7% of men in this age group and 22.2 percent of women in this age group). The market for gastric cancer is anticipated to grow in the region as a result.
The US market dominated the North America Gastric Cancer Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,377.4 million by 2029. The Canada market is poised to grow at a CAGR of 19.8% during (2023-2029). Additionally, The Mexico market should witness a CAGR of 18.7% during (2023-2029).
Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, and Radiation Therapy & Surgery. Based on Disease Type, the market is segmented into Adenocarcinoma, Carcinoid Tumor, Gastrointestinal Stromal Tumor, Lymphoma and Others. Based on Distribution Channel, the market is segmented into Specialty & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Drug Class, the market is segmented into PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Pfizer, Inc., Viatris, Inc. (Mylan N.V.), F. Hoffmann-La Roche Ltd., Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceuticals Industries Ltd., Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., and Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.).
Scope of the Study
By Route of Administration
- Injectable
- Oral
By Treatment Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Radiation Therapy & Surgery
By Disease Type
- Adenocarcinoma
- Carcinoid Tumor
- Gastrointestinal Stromal Tumor
- Lymphoma
- Others
By Distribution Channel
- Specialty & Retail Pharmacies
- Hospital Pharmacies
- Others
By Drug Class
- PD-1/PD-L1 Inhibitors
- HER2 Antagonists
- VEGFR2 Antagonists
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Pfizer, Inc.
- Viatris, Inc. (Mylan N.V.)
- F. Hoffmann-La Roche Ltd.
- Eli Lilly And Company
- Merck & Co., Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bristol Myers Squibb Company
- Celltrion Healthcare Co., Ltd.
- Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. North America Gastric Cancer Market by Route of Administration
Chapter 5. North America Gastric Cancer Market by Treatment Type
Chapter 6. North America Gastric Cancer Market by Disease Type
Chapter 7. North America Gastric Cancer Market by Distribution Channel
Chapter 8. North America Gastric Cancer Market by Drug Class
Chapter 9. North America Gastric Cancer Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Novartis AG
- Pfizer, Inc.
- Viatris, Inc. (Mylan N.V.)
- F. Hoffmann-La Roche Ltd.
- Eli Lilly And Company
- Merck & Co., Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bristol Myers Squibb Company
- Celltrion Healthcare Co., Ltd.
- Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)
Methodology
LOADING...
